Zalasta (olanzapine)
- Region
- 🇪🇺 EU
- Active substance
- olanzapine
- Company
- KRKA tovarna zdravil d.d. Novo mesto
- Status
- Authorised
- Therapeutic area
- Schizophrenia; Bipolar Disorder
- EU approval
- Thu 27 Sep 2007
- Designations
- Generic
- Application
- EMEA/H/C/000792
- ATC
- N05AH03
- Official record
- www.ema.europa.eu
Indication
Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇺🇸 Weltruza Approved · Teva
- 🇪🇺 Olazax Authorised · Glenmark Pharmaceuticals s.r.o.
- 🇪🇺 Zypadhera Authorised · CHEPLAPHARM Registration GmbH
- 🇪🇺 Olazax Disperzi Authorised · Glenmark Pharmaceuticals s.r.o.
- 🇪🇺 Olanzapine Glenmark Authorised · Glenmark Arzneimittel GmbH
- 🇪🇺 Olanzapine Glenmark Europe Authorised · Glenmark Arzneimittel GmbH
- 🇪🇺 Zyprexa Authorised · CHEPLAPHARM Registration GmbH
- 🇪🇺 Olanzapine Viatris (previously Olanzapine Mylan) Authorised · Viatris Limited
- 🇪🇺 Olanzapine Apotex Withdrawn · Apotex Europe BV
- 🇪🇺 Olanzapine Teva Authorised · Teva B.V.
- 🇪🇺 Zyprexa Velotab Authorised · CHEPLAPHARM Registration GmbH
- 🇪🇺 Olanzapine Cipla (previously Olanzapine Neopharma) Withdrawn · Cipla (EU) Limited
Follow Zalasta
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.